Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

A comparative study of zoledronic acid and once weekly Alendronate in the management of acute Charcot arthropathy of foot in patients with diabetes mellitus.

Bharath R, Bal A, Sundaram S, Unnikrishnan AG, Praveen VP, Bhavani N, Nair V, Jayakumar RV, Kumar H.

Indian J Endocrinol Metab. 2013 Jan;17(1):110-6. doi: 10.4103/2230-8210.107818.

2.

The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial.

Pakarinen TK, Laine HJ, Mäenpää H, Mattila P, Lahtela J.

Diabetes Care. 2011 Jul;34(7):1514-6. doi: 10.2337/dc11-0396. Epub 2011 May 18.

3.
4.

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.

McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.

Bone. 2007 Jul;41(1):122-8. Epub 2007 Mar 24.

PMID:
17468062
5.

Acute Charcot arthropathy in patients with diabetes mellitus: healing times by foot location.

Sinacore DR.

J Diabetes Complications. 1998 Sep-Oct;12(5):287-93.

PMID:
9747646
6.

Sympathetic neuropathy in diabetes mellitus patients does not elicit Charcot osteoarthropathy.

Christensen TM, Simonsen L, Holstein PE, Svendsen OL, Bülow J.

J Diabetes Complications. 2011 Sep-Oct;25(5):320-4. doi: 10.1016/j.jdiacomp.2011.06.006. Epub 2011 Aug 2.

PMID:
21813289
7.

Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.

Craig SJ, Youssef PP, Vaile JH, Sullivan L, Bleasel JF.

Intern Med J. 2011 Feb;41(2):186-90. doi: 10.1111/j.1445-5994.2010.02198.x.

PMID:
20214696
8.

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.

J Bone Miner Res. 2010 Oct;25(10):2239-50. doi: 10.1002/jbmr.119.

9.

Charcot neuro-osteoarthropathy-current standards.

Petrova NL, Edmonds ME.

Diabetes Metab Res Rev. 2008 May-Jun;24 Suppl 1:S58-61. doi: 10.1002/dmrr.846. Review.

PMID:
18442182
10.

Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.

Woodis CB.

Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27.

PMID:
18505912
11.

Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: a prospective randomized trial.

Pakarinen TK, Laine HJ, Mäenpää H, Kähönen M, Mattila P, Lahtela J.

Foot Ankle Surg. 2013 Jun;19(2):121-4. doi: 10.1016/j.fas.2012.12.007. Epub 2013 Feb 20.

PMID:
23548455
12.

Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).

Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.

Acta Pol Pharm. 2002 Nov-Dec;59(6):478-82.

13.

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.

Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ.

Aging (Milano). 2000 Feb;12(1):1-12.

PMID:
10746426
14.

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.

N Engl J Med. 2005 Sep 1;353(9):898-908.

15.

A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis - monthly (four weeks) intravenous versus once weekly oral administrations.

Shiraki M, Nakamura T, Fukunaga M, Sone T, Usami A, Inoue T.

Curr Med Res Opin. 2012 Aug;28(8):1357-67. doi: 10.1185/03007995.2012.709838. Epub 2012 Jul 20.

PMID:
22769235
16.

The effectiveness of non-surgical interventions in the treatment of Charcot foot.

Smith C, Kumar S, Causby R.

Int J Evid Based Healthc. 2007 Dec;5(4):437-49. doi: 10.1111/j.1479-6988.2007.00081.x.

PMID:
21631804
17.

Duration of off-loading and recurrence rate in Charcot osteo-arthropathy treated with less restrictive regimen with removable walker.

Christensen TM, Gade-Rasmussen B, Pedersen LW, Hommel E, Holstein PE, Svendsen OL.

J Diabetes Complications. 2012 Sep-Oct;26(5):430-4. doi: 10.1016/j.jdiacomp.2012.05.006. Epub 2012 Jun 12.

PMID:
22699112
18.

Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.

Jude EB, Selby PL, Burgess J, Lilleystone P, Mawer EB, Page SR, Donohoe M, Foster AV, Edmonds ME, Boulton AJ.

Diabetologia. 2001 Nov;44(11):2032-7.

PMID:
11719835
19.
20.

[Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].

Wang HY, Lin XP, Hao CL, Zhang CQ, Sun BQ, Zheng JP, Chen P, Sheng JY, Wu A, Zhong NS.

Zhonghua Jie He He Hu Xi Za Zhi. 2006 Oct;29(10):679-87. Chinese.

PMID:
17129496

Supplemental Content

Support Center